Bristol Myers Squibb Pipeline Readouts: Why a 9.7x Forward P/E Sets Up a $70 Target Before the 2028 Patent Cliff
Bristol Myers Squibb pipeline readouts: milvexian, Cobenfy and admilparant data vs. the 2028 cliff. 9.7x forward P/E, 4% yield, $70 target.
